Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited (SBMFF) Revenue
Annual & quarterly revenue history · segment & region breakdown
SBMFF · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsSino Biopharmaceutical Limited trailing twelve-month (TTM) revenue is $30.57B, an increase of 7.44% year-over-year from $31.01B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $31.01B | +$2.15B | +7.44% |
| 2024-12-31 | $28.87B | +$2.67B | +10.18% |
| 2023-12-31 | $26.20B | +$0.17B | +0.67% |
| 2022-12-31 | $26.03B | -$0.84B | -3.11% |
| 2021-12-31 | $26.86B | +$3.21B | +13.59% |
| 2020-12-31 | $23.65B | -$0.59B | -2.42% |
| 2019-12-31 | $24.23B | +$3.35B | +16.02% |
| 2018-12-31 | $20.89B | +$6.07B | +40.96% |
| 2017-12-31 | $14.82B | +$0.65B | +4.58% |
| 2016-12-31 | $14.17B | +$1.99B | +16.30% |
Compare revenue vs peers
BiotechnologyCompare SBMFF revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Sino Biopharmaceutical Limited receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Sino Biopharmaceutical Limited reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CNY.
Data sourced from Sino Biopharmaceutical Limited's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
SBMFF revenue · 4 questionsSBMFF's trailing twelve-month (TTM) revenue is $30.57B. That is an increase of 7.44% year-over-year from $31.01B in FY2025.
▸ Source: FMP · Sino Biopharmaceutical Limited SEC filings · GAAP · Sino Biopharmaceutical Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026